A Functional Magnetic Resonance Imaging (fMRI) Study in Overweight and Obese Men (0000-103)
A Functional Magnetic Resonance Imaging (fMRI) Study of the Reproducibility and the Effect of Sibutramine During Fasted and Fed Conditions in Healthy Overweight and Obese Men
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is a male between 18 and 45 years of age
- Subject has a body mass index (BMI) between 28 and 35 kg/m^2
- Subject does not weigh more than 140 kg (309 lbs) at the screening visit
- Subject is right-handed
- Subject is a non-smoker
- Subject is in generally good health
- Subject has normal or corrected to normal vision
Exclusion Criteria:
- Subject works a night shift within 3 days of each treatment visit
- Subject has permanent cosmetic or metallic objects in his body
- Subject has attention deficit hyperactivity disorder (ADHD)
- Subject has or had sleep apnea
- Subject has a history of neurological disorders
- Subject has a history of any clinically significant disease or condition
- Subject is vegan or vegetarian
- Subject has a history of eating disorders
- Subject has had previous bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: 2
Placebo
|
Single dose placebo to sibutramine in two of three treatment periods.
|
|
ACTIVE_COMPARATOR: 1
Sibutramine
|
Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average percent signal change of the top 20% of activated voxels (AvgPSC20) during the fasted condition over six primary brain regions of interest (ROI)
Time Frame: Day 1
|
Day 1
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Intraclass coefficient of correlation of the AvgPSC20 assessed during the fed and fasted conditions over the six ROIs
Time Frame: Day 1
|
Day 1
|
|
Regional cerebral blood flow (rCBF) during the fasted condition with placebo or sibutramine in the six ROIs
Time Frame: Day 1
|
Day 1
|
|
AvgPSC20 in the fed condition with placebo or sibutramine in the six ROIs
Time Frame: Day 1
|
Day 1
|
|
Difference in PSC20 during fasted and fed conditions with placebo or sibutramine in the six ROIs
Time Frame: Day 1
|
Day 1
|
|
rCBF during the fed condition with placebo or sibutramine in the six ROIs
Time Frame: Day 1
|
Day 1
|
|
Difference in rCBF during fasted and fed conditions with placebo or sibutramine in the six ROIs
Time Frame: Day 1
|
Day 1
|
|
Test-retest reliability of rCBF in the six ROIs during the fasted and fed states in men receiving placebo
Time Frame: Day 1
|
Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0000-103
- 103
- 2009_597
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.